European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug
Pharming's leniolisib trial shows positive results for children with APDS. FDA approved leniolisib for older patients, expanding potential market. Study included 21 children; all completed treatment without serious side effects. Improvements observed in lymphoproliferation and B cell counts. Regulatory filings planned for leniolisib's pediatric approval starting in 2025.
View signal analysis